CancerDrs

Cervical Cancer clinical trials in North Carolina

37 actively recruiting cervical cancer trials at 27 sites across North Carolina.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 2 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 3 Recruiting Industry

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refract…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07276399
Sites in North Carolina:
  • Carolina Cancer Research Center — Wilson, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-ra…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT02734537
Sites in North Carolina:
  • UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
  • Southeastern Medical Oncology Center-Clinton — Clinton, North Carolina
  • Southeastern Medical Oncology Center-Goldsboro — Goldsboro, North Carolina
  • Wayne Memorial Hospital — Goldsboro, North Carolina
  • Onslow Memorial Hospital — Jacksonville, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

This phase II trial tests the addition of chemotherapy, with carboplatin and paclitaxel, or chemo-immunotherapy, with carboplatin, paclitaxel and cemiplimab to standard salvage surgery followed by post operative radiation therapy and cispl…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07195734
Sites in North Carolina:
  • UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
  • Carolinas Medical Center/Levine Cancer Institute — Charlotte, North Carolina
  • Atrium Health Cabarrus/LCI-Concord — Concord, North Carolina
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…

Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in North Carolina:
  • Local Institution - 2144 — Goldsboro, North Carolina
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…

Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in North Carolina:
  • Duke University — Durham, North Carolina
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383. The main questions if aims to answer are: * Does CP-383 slow or stop the growth of…

Sponsor: Tasca Therapeutics
NCT ID: NCT07030257
Sites in North Carolina:
  • Carolina BioOncology Institute — Huntersville, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CN…

Sponsor: Apollomics Inc.
NCT ID: NCT03175224
Sites in North Carolina:
  • University of North Carolina — Chapel Hill, North Carolina
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-101/GI-101A as a single agent or in combination with pembrolizumab or lenvatinib over a range of advanced and/or metastatic…

Sponsor: GI Innovation, Inc.
NCT ID: NCT04977453
Sites in North Carolina:
  • Carolina Biooncology Institute — Huntersville, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Lerapolturev (PVSRIPO) in GBM

The purpose of this research study is to determine the safety and efficacy of administering two doses of lerapolturev in residual disease (within tumor margins) after surgery, followed later by repeated injections of lerapolturev in the su…

Sponsor: Darell Bigner
NCT ID: NCT06177964
Sites in North Carolina:
  • Duke University Medical Center — Durham, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal Adenocarcinoma

The goal of this trial is to learn if adding consolidative chemotherapy to routine chemoradiation can better control both local recurrence and metastasis and reduce the need for surgical intervention.

Sponsor: Duke University
NCT ID: NCT07603375
Sites in North Carolina:
  • Duke University Medical Center — Durham, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Effects of Infusion Timing on Treatment Response in Solid Tumors

This study evaluates whether the time of day when immunotherapy is given affects clinical outcomes. It includes patients eligible for PD-1 (programmed cell death protein 1) or PD-L1 (programmed death-ligand 1) inhibitor treatment who have …

Sponsor: UNC Lineberger Comprehensive Cancer Center
NCT ID: NCT07630168
Sites in North Carolina:
  • University of North Carolina at Chapel Hill, Department of Radiation Oncology — Chapel Hill, North Carolina
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…

Sponsor: Exelixis
NCT ID: NCT05176483
Sites in North Carolina:
  • Exelixis Clinical Site #12 — Durham, North Carolina
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. Head and Neck Squamous Ce…

Sponsor: AbbVie
NCT ID: NCT05005403
Sites in North Carolina:
  • Duke Cancer Institute /ID# 276267 — Durham, North Carolina
  • Carolina BioOncology Institute /ID# 232597 — Huntersville, North Carolina
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study of XB010 in Subjects With Solid Tumors

This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic solid tumo…

Sponsor: Exelixis
NCT ID: NCT06545331
Sites in North Carolina:
  • Carolina BioOncology Institute — Huntersville, North Carolina
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

The study will assess the safety, PK, PD, and preliminary efficacy of ABBV-CLS-484 as monotherapy and in combination with a PD-1 targeting agent or with a or a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (…

Sponsor: Calico Life Sciences LLC
NCT ID: NCT04777994
Sites in North Carolina:
  • Duke Cancer Center /ID# 251975 — Durham, North Carolina
  • Carolina BioOncology Institute /ID# 225704 — Huntersville, North Carolina
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driv…

Sponsor: Bicara Therapeutics
NCT ID: NCT04429542
Sites in North Carolina:
  • Levine Cancer Institute — Charlotte, North Carolina
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas

Sponsor: Dren Bio
NCT ID: NCT06999187
Sites in North Carolina:
  • Dren Investigational Site — Huntersville, North Carolina
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-711 as a monotherapy and in comb…

Sponsor: AbbVie
NCT ID: NCT07241039
Sites in North Carolina:
  • Carolina BioOncology Institute /ID# 272380 — Huntersville, North Carolina
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

The purpose of this first-in-human (FIH) study is to evaluate the safety, tolerability, Pharmacokinetics (PK), and preliminary clinical activity of M7437 in participants with locally advanced or metastatic solid tumors with known Ly6E expr…

Sponsor: EMD Serono Research & Development Institute, Inc.
NCT ID: NCT07360314
Sites in North Carolina:
  • Carolina BioOncology Institute, LLC - Cancer Therapy and Research Center — Huntersville, North Carolina
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events, change in disease activity and pharmacokinetics of ABBV-253. ABBV-253 is an investigatio…

Sponsor: AbbVie
NCT ID: NCT07807956
Sites in North Carolina:
  • Carolina BioOncology Institute /ID# 283064 — Huntersville, North Carolina
View on ClinicalTrials.gov →
Phase 1 Recruiting Academic/Other

XL092 and Cemiplimab in BRAF WT Thyroid Cancer

This multicenter study examines the safety and feasibility of the combination of neoadjuvant XL092 and cemiplimab prior to surgical resection in participants with wild-type (WT) anaplastic thyroid cancer (ATC) that has a BRAF mutation (BRA…

Sponsor: UNC Lineberger Comprehensive Cancer Center
NCT ID: NCT06902376
Sites in North Carolina:
  • University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
View on ClinicalTrials.gov →
Phase 1 Recruiting Academic/Other

Hyaluronic Acid-based Gel Spacers in Gynecologic Malignancies

This pilot feasibility study evaluates the use of a hyaluronic acid-based spacing gel (Barrigel) in participants with cervical cancer undergoing chemoradiotherapy (chemoRT), including brachytherapy, as part of standard care. The primary go…

Sponsor: UNC Lineberger Comprehensive Cancer Center
NCT ID: NCT07292818
Sites in North Carolina:
  • Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill — Chapel Hill, North Carolina
View on ClinicalTrials.gov →
Phase 1 Recruiting Academic/Other

Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC

The purpose of this study is to test the safety and tolerability of using a new treatment called autologous T lymphocyte chimeric antigen receptor cells against the CSPG4 antigen (iC9.CAR-CSPG4 T cells) in patients with head and neck cance…

Sponsor: UNC Lineberger Comprehensive Cancer Center
NCT ID: NCT06096038
Sites in North Carolina:
  • Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill — Chapel Hill, North Carolina
View on ClinicalTrials.gov →
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in North Carolina:
  • AdventHealth Infusion Center Asheville — Asheville, North Carolina
  • UNC Health Cancer Care Cary — Cary, North Carolina
  • Southeastern Medical Oncology Center-Clinton — Clinton, North Carolina
  • AdventHealth Infusion Center Haywood — Clyde, North Carolina
  • Durham VA Medical Center — Durham, North Carolina
View on ClinicalTrials.gov →

Showing 25 of 37 trials with sites in North Carolina. See all cervical cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-11-09